11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

Skip to main content

Advertisement

Search

Log in

Drug Evaluation
Published: 27 October 2012

S-Adenosyl-L-Methionine
A Review of its Pharmacological Properties and Therapeutic Potential in Liver Dysfunction and Affective
Disorders in Relation to its Physiological Role in Cell Metabolism

Heather A. Friedel 1,
Karen L. Goa1 &
Paul Benfield1 

Drugs
volume 38, pages 389–416 (1989)Cite this article

62 Accesses

161 Citations

6 Altmetric

Metrics details

Summary
Synopsis
S-Adenosyl-L-methionine (SAMe) is a naturally occurring molecule distributed to virtually all body tissues and
fluids. It is of fundamental importance in a number of biochemical reactions involving enzymatic
transmethylation, contributing to the synthesis, activation and/or metabolism of such compounds as hormones,
neurotransmitters, nucleic acids, proteins, phospholipids and certain drugs. The administration of a stable salt of
SAMe, either orally or parenterally, has been shown to restore normal hepatic function in the presence of
various chronic liver diseases (including alcoholic and non-alcoholic cirrhosis, oestrogen-induced and other
forms of cholestasis), to prevent or reverse hepatotoxicity due to several drugs and chemicals such as alcohol,
paracetamol (acetaminophen), steroids and lead, and to have antidepressant properties. In all of these studies

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 1/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

SAMe has been very well tolerated, a finding of great potential benefit given the well-known adverse effects of
tricyclic antidepressants with which it has been compared in a few trials.

Thus, with its novel mechanisms of action and good tolerability, SAMe is an interesting new therapeutic agent
in several diverse disease conditions, but its relative value remains to be determined in appropriate comparisons
with other treatment modalities in current use.

Role of S-Adenosyl-L-Methionine in Cell Biochemistry

S-Adenosyl-L-methionine (commonly known as SAMe) acts as a methyl group donor in many transmethylation
reactions, including those involved with the biosynthesis of phospholipids which play several important roles
within the cell membrane. These roles include regulation of cellular enzymatic and bioelectrical activity and the
maintenance of membrane fluidity. Loss of the latter in brain cells of aged animals has been linked with loss of
dopaminergic and β-adrenergic binding sites and changes in cell membrane composition. The exogenous
administration of SAMe maintains normal phospholipid ratios and restores enzymatic activity leading to
normalisation of metabolic processes within the cell. This may explain, at least in part, the effect of SAMe in
normalising several indices of hepatic function which are altered in chronic liver disease where changes in cell
membrane composition and enzymatic activity of hepatocytes have been demonstrated. Activation of enzymes
which affect the synthesis and metabolism of neurotransmitters may also be related to maintenance of normal
cell membrane function and may explain the effects of SAMe on mood in patients with affective disorders.

Release of methyl groups from the SAMe molecule results in activation of the transsulphuration pathway
leading to the formation of glutathione, the main cellular antioxidant responsible for the detoxification of
various compounds, including lead and paracetamol. Thus, regulation of the transsulphuration pathway is an
important effect and one which may be responsible for its beneficial action on drug-and chemical-induced liver
disease.

The almost universal distribution of SAMe in body tissues and its complex role in metabolic processes, all of
which depend in some way on methylation reactions, complicate the complete characterisation of its effects on
cellular biochemistry. As a result the mechanism of its actions in various diverse disease states remains
speculative.

Pharmacodynamic Properties of Exogenous SAMe

The role of SAMe in transmethylation reactions and as a precursor of sulphur-containing compounds via the
transsulphuration pathway is fundamentally important in the liver, as both pathways have been shown to be
abnormal in the presence of liver disease. In the presence of cirrhosis, methionine metabolism is decreased, and
the activities of S-adenosyl-methionine synthetase and phospholipid methyltransferase are reduced, possibly
leading to lessened production of sulphated compounds and phosphatidylcholine. Levels of the important thiol
compounds glutathione and cysteine are reduced in plasma.

Various animal models have been used to demonstrate the protective effect of SAMe against intrahepatic
cholestasis induced by a range of compounds, including oestrogen. The mechanism of action of SAMe in
oestrogen-induced cholestasis appears to be via increased enzyme activity and fluidity of liver plasma
membranes, and maintenance of phospholipid activity in bile salt transport systems. Preliminary findings of a
preventative effect of SAMe in women with oestrogen-induced cholestasis have been augmented by results of
small therapeutic trials (see below).

Acute toxicity studies in animals reveal that SAMe can prevent mortality induced by paracetamol
(acetaminophen) and acute and chronic lead poisoning. Some success has been achieved with the use of SAMe
in treating patients with lead poisoning (see below). Maintenance of glutathione stores is instrumental in the
prevention by SAMe of hepatotoxicity due to these agents.

SAMe administered to rats and baboons subjected to chronic ethanol ingestion has been shown to maintain or
prevent depletion of glutathione levels, to normalise mitochondrial enzyme activity, and to prevent production
of acetaldehyde and deposition of fat in the liver. In healthy volunteers, plasma concentrations of ethanol and
acetaldehyde were significantly lower when SAMe was ingested concomitantly with ethanol.

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 2/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

SAMe has been shown in animals and humans to be distributed to the brain where it stimulates the activity of
dopaminergic and serotonergic pathways, probably through its involvement in transmethylation processes.
Levels of SAMe, and of 5-hydroxy indoleacetic acid (5HIAA) and homovanillic acid, increase in the
cerebrospinal fluid of humans after administration of SAMe. The interplay of folate and SAMe pathways in
influencing mood is a topic of considerable study, with recent work linking red cell folate levels to levels of
5HIAA in cerebrospinal fluid. Reductions in S-adenosyl-methionine syntlietase and phosphatidylcholine in
erythrocytes of depressed patients suggest a disruption of SAMe-dependent pathways, and form the basis for the
use of SAMe in depressed patients (see below).

SAMe has been shown invitroto enhance ATP levels in erythrocytes, enabling restoration of cell shape and
conservation of deformability. Invivo, blood viscosity was reduced following injection of SAMe.

Pharmacokinetic Properties
Limited trials in healthy volunteers have demonstrated very low bioavailability after oral administration of
SAMe, indicative of a significant first-pass effect and rapid metabolism in the liver. Peak plasma concentrations
obtained with an enteric-coated tablet formulation are dose related, with a peak plasma concentration of 0.5 to 1
mg/L achieved 3 to 5 hours after single doses in the range of 400 to 1000mg.

Single intravenous doses of SAMe (100 and 500mg) have yielded volumes of distribution of 0.41 and 0.44
L/kg, respectively. Plasma protein binding is 5% or less. The rate of distribution to all body tissues is related to
their degree of vascularity and blood flow. SAMe crosses the blood-brain barrier, with slow accumulation in the
cerebrospinal fluid. Animal data suggest that exogenously administered SAMe follows the same metabolic
pathways as the endogenous compound, namely, transmethylation, transsulphuration and decarboxylation. By
24 hours after intravenous administration of SAMe 100 or 500mg in healthy volunteers, 34% and 40% of
unchanged drug, respectively, had appeared in urine. Urinary excretion of an oral 200mg dose of SAMe has
been reported as 15.5% in 48 hours with faeces containing 23.5% at 72 hours. The remainder was probably
incorporated into stable cellular pools. The half-life of SAMe in healthy volunteers was 80 to 100 minutes and
121 ininutes in a small group of patients with chronic liver disease.

Use in Patients with Liver Dysfunction

Trials in small numbers of patients with various types of chronic liver disease, including biliary or alcoholic
cirrhosis, hepatitis or drug-induced cholestasis, have confirmed the short term effect of SAMe (intravenously or
orally) relative to placebo in normalising measures of liver function (e.g. plasma levels of aspartate
aminotransferase, γ-glutamyl transpeptidase, alkaline phosphatase, cysteine, taurine and methionine). Patients
with chronic lead poisoning have shown reversal of liver enzyme abnormalities after SAMe therapy. Moreover,
severe pruritus has been ameliorated in patients with cholestasis of diverse aetiology.

Of interest is the apparent ability of SAMe, when given concomitantly, to protect against hepatic dysfunction
caused by other drugs, including steroids, certain anticon-vulsants, and tricyclic antidepressants, paracetamol
and alcohol. SAMe was effective in normalising biochemical parameters in small groups of patients with
metabolic disorders of bilirubin and porphyrin metabolism, such as Gilbert’s syndrome and infantile porphyria
cutanea tarda.

Use in Patients with Affective Disorders

The major effect of SAMe in depressed patients is elevation of mood, the precise mechanism of which is
unknown. Non-comparative trials in small groups of patients with various types of depression have shown a
consistent improvement in mood with SAMe in daily dosages up to 1600mg orally or 500mg parenterally for up
to 6 weeks, as determined by the Hamilton rating scale, with those patients recently diagnosed or previously
responding to antidepressants being most improved. In a number of short term randomised, double-blind trials
SAMe 75 to 400mg administered parenterally was consistently superior to placebo and was at least as effective
as other antidepressant drugs administered parenterally (nomifensine, amitriptyline, imipramine and
clomipramine), generally having an onset of action within the first 2 weeks of treatment. Furthermore, in
combination with another agent (the β2-agonist fenoterol, mianserin or clomipramine), SAMe shortened the
latency period and improved the response as compared with the other drug alone. The use of SAMe as an
adjunct to treatment with other antidepressants is worthy of study if the time to treatment response can be

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 3/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

reduced, especially in suicidal patients. Furthermore SAMe treatment was well tolerated, an asset in patients
who experience significant adverse effects from tricyclic antidepressant therapy. The relative efficacy of SAMe
administered orally should be pursued in longer term trials.

Use in Other Disorders

The wide range of effects of SAMe administration has led to the investigation of its use in many diverse
conditions. Isolated reports have included clinical trials involving patients with Alzheimer’s; disease and
epilepsy, where its effect was predominantly on mood but no change in the underlying condition could be
demonstrated; migraine, where the incidence and severity of attacks was reduced; and primary fibromyalgia,
where both joint pain and associated depression were improved. However, none of the above effects of SAMe
have been adequately studied in well-designed trials s’uch that any conclusions can be drawn regarding its
possible efficacy.

Adverse Effects

SAMe is very well tolerated. At oral doses of up to 1600mg daily no adverse effects have been noted other than
occasional mild gastrointestinal effects. In a study of 20,641 patients with osteoarthritis the tolerability was
assessed as good to very good in 87% of patients, the withdrawal rate being 5.2%, primarily early in treatment
when doses were highest. In depressed patients tolerability was also good, with only a few patients developing
anxiety. However, the transition from depression to hypomania was noted in some patients with bipolar illness.

Dosage
The recommended daily dose of SAMe for the treatment of liver disorders, such as cholestasis, is 800mg
parenterally or 1600mg orally. For parenteral administration in depressive illness 200 to 400 mg/day should be
given for 15 to 20 days. Oral therapy is in the dose range 400 to 1600 mg/day.

This is a preview of subscription content, access via your institution.

Access options

Rent this article via DeepDyve.

Buy article PDF

39,95 €
Price includes VAT (India)

Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Learn more about Institutional subscriptions

References
1. Adachi Y, Nanno T, Kanbe A, Inufusa H, Yamashita M, et al. The effects of S-adenosylmethionine on
intrahepatic cholestasis. Japanese Archives of Internal Medicine 33: 185–192, 1986

Google Scholar 
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 4/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

2. Agnoli A, Andreoli V, Casacchia M, Cerbo R. Effect of S-adenosyl-L-methionine (SAMe) upon

depressive symptoms. Journal of Psychiatric Research 13: 43–54, 1976

PubMed 
CAS 
Google Scholar 

3. Agnoli A, Martucci N, Manna V. On the antidepressant effect of SAMe: clinical and pharmaco-EEG
study with SAMe alone and in association with a beta-2 stimulant drug, phenoterole. Clinical
Neuropharmacology 7 (Suppl. 1): 104–105, 1984

Google Scholar 

4. Altomare E, Vendemiale G, Marchesini G, Le Grazie C, Di Padova C. Increased bioavailability of

sulfurated compounds after S-adenosylmethionine (SAMe) administration to alcoholics. In Kuriyama et
al. (Eds) Biomedical and social aspects of alcohol and alcoholism, pp. 353–356, Elsevier Science
Publishers B.V., 1988

Google Scholar 

5. Alvarez E. SAMe and depression. In Mato (Ed.) 1st Conference on biomedical pharmacological and
clinical aspects of transmethylation, pp. 107–114, Spain, 1986

Google Scholar 

6. Alvarez E, Udina C, Guillamat R. Shortening of latency period in depressed patients treated with SAM
and other antidepressant drugs. Cell Biology Reviews S1: 103–110, 1987

Google Scholar 

7. Andreoli V, Campedelli A, Maffei F. La S-adenosil-L-metionina (SAMe) in geropsichiatria: uno studio

clinico controllato « in a perto » nelle sindromi depressive dell’eta senile. Giornale di Gerontologia 25:
172–180, 1977

Google Scholar 

8. Arias IM. Ion transport into and out of the liver. In Keppler D, Popper H, Bianchi L, et al. (Eds)
Mechanisms of hepatocyte injury and death, pp 49–56, MTP Press, Lancaster, UK, 1983

Google Scholar 

9. Arias IM. Mechanisms and consequences of ion transport in the liver. In Popper H, Schaffner F (Eds)
Progress in liver diseases, vol. III, pp. 145–159, Grune & Stratton Inc, Orlando, USA, 1986

Google Scholar 

10. Artale F, Francisci A, Espureo M, Sergio G, Cramarossa L, et al. Effects of S-adenosyl-L-methionine on

hemorheological changes induced by exercise in patients with peripheral occlusive arterial diseases.
Current Therapeutic Research 32: 520–528, 1982

Google Scholar 

11. Baldessarini RJ. Neuropharmacology of S-adenosyl-L-methionine. American Journal of Medicine 83

(Suppl. 5A): 95–103, 1987

PubMed 
CAS 
Google Scholar 

12. Baldessarini RJ, Kopin IJ. S-Adenosyl-L-methionine in brain and other tissues. Journal of
Neurochemistry 13: 769–777, 1966

PubMed 
CAS 
Google Scholar 

13. Barber JR, Morimoto BH, Brunauer LS, Clarke S. Metabolism of S-adenosyl-L-methionine in intact
human erythrocytes. Biochimica et Biophysica Acta 887: 361–372, 1986
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 5/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

Google Scholar 

14. Batlle AM Del C, Paredes SR, Fukuda H, Kozicki PA, Rossetti MV. S-adenosyl-L-methionine, a
mechanism for its action on lead mobilisation and disposal in lead poisoning. Biochemical Archives 2:
293–303, 1986

Google Scholar 

15. Batlle AM Del C, Stella AM, De Kaminsky AR, Kaminsky C, Mariano HG. Two cases of infantile
porphyria cutanea tarda: successful treatment with oral S-adenosyl-L-methionine and low-dose oral
chloroquine. British Journal of Dermatology 116: 407–415, 1987

Google Scholar 

16. Bell KM, Plon L, Bunney Jr WE, Potkin SG. S-adenosylmethionine treatment of depression: a controlled
clinical trial. American Journal of Psychiatry 145: 1110–1114, 1988

PubMed 
CAS 
Google Scholar 

17. Berger R, Nowak H. A new medical approach to the treatment of osteoarthritis: report of an open phase
IV study with ademetionine (Gumbaral). American Journal of Medicine 83 (Suppl. 5A): 84–88, 1987

PubMed 
CAS 
Google Scholar 

18. Boelsterli UA, Rakhit G, Balazs T. Modulation by S-adenosyl-L-methionine of hepatic Na+, K+-ATPase,
membrane fluidity, and bile flow in rats with ethinyl estradiol-induced cholestasis. Hepatology 3: 12–17,
1983

PubMed 
CAS 
Google Scholar 

19. Bombardieri G, Milani A, Bernardi L, Rossi L. Effects of S-ad-enosyl-methionine (SAMe) in the

treatment of Gilbert’s syndrome. Current Therapeutic Research 37: 580–585, 1985

Google Scholar 

20. Bombardieri G, Pappalardo G, Bernardi L, Barra D, Di Palma A, et al. Intestinal absorption of S-

adenosyl-L-methionine in humans. International Journal of Clinical Pharmacology, Therapy and
Toxicology 21: 186–188, 1983

CAS 
Google Scholar 

21. Bottiglieri T, Chary TK, Laundy M, Carney MWP, Godfrey P, et al. Transmethylation in depression.
Alabama Journal of Medical Sciences 25: 296–301, 1988

PubMed 
CAS 
Google Scholar 

22. Bottiglieri T, Laundy M, Martin R, Carney MWP, Nissenbaum H, et al. S-adenosyl-methionine influences
monoamine metabolism. Lancet 2: 224, 1984

PubMed 
CAS 
Google Scholar 

23. Burk RF. Hepatocytoprotective substances. Gastroenterology 81: 397–398, 1981

PubMed 
CAS 
Google Scholar 

24. Cabrero C, Martin Duce A, Ortiz P, Alemany S, Mato JM. Specific loss of the high-molecular-weight
form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. Hepatology 88: 1530–1534, 1988

Google Scholar 

25. Cacciatore L, Cozzolino G, Varriale A, Dionisio M. Treatment of pruritus in chronic liver disease with S-
adenosylmethionine. European Journal of Clinical Investigation 19 (Part II): A15, 1989
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 6/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

Google Scholar 

26. Carney MWP. Review. Neuropharmacology of S-adenosylmethionine. Clinical Neuropharmacology 9:

235–243, 1986

PubMed 
CAS 
Google Scholar 

27. Carney MWP, Chary TKN, Bottiglieri T. Switch mechanism in affective illness and oral S-
adenosylmethionine (SAM). British Journal of Psychiatry 150: 724–725, 1987

PubMed 
CAS 
Google Scholar 

28. Carney MWP, Chary TKN, Bottiglieri T, Reynolds EH. Switch and S-adenosyl-methionine. Alabama
Journal of Medical Sciences 25: 316–319, 1988

PubMed 
CAS 
Google Scholar 

29. Carney MWP, Martin R, Bottiglieri T, Reynolds EH, Nissenbaum H, et al. Switch mechanism in affective
illness and S-adenosylmethionine. Lancet 1: 820–821, 1983

PubMed 
CAS 
Google Scholar 

30. Carney MWP, Edeh J, Bottiglieri T, Reynolds EM, Toone BK. Affective illness and S-
adenosylmethionine: a preliminary report. Clinical Neuropharmacology 9: 379–385, 1986

PubMed 
CAS 
Google Scholar 

31. Caruso I, Fumagalli M, Boccassini L, Sarzi Puttini P, Santandrea S, et al. Treatment of depression in
rheumatoid arthritic patients: a comparison of S-adenosylmethionine (Samyr®) and placebo in a double-
blind study. Clinical Trials Journal 24: 305–310, 1987

Google Scholar 

32. Celani T, Iorio G, Vacca L, Amati A, Del Vecchio M. Electroen-cephalographic control with frequency
analysis in depressed patients treated with SAMe. Current Therapeutic Research 23: 525–527, 1978

Google Scholar 

33. Chawla RK, Lewis FW, Kutner MH, Bate DM, Roy RGB et al. Plasma cysteine, cystine, and glutathione
in cirrhosis. Gastroenterology 87: 770–776, 1984

PubMed 
CAS 
Google Scholar 

34. Cibin M, Gentile N, Ferri M, Canton G, Gallimberti L. S-adenosylmethionine (SAMe) is effective in

reducing ethanol abuse in an outpatient program for alcoholics. In Kuriyama et al. (Eds) Biomedical and
social aspects of alcohol and alcoholism, pp. 357–360, Elsevier Science Publishers B.V., 1988

Google Scholar 

35. Cimino M, Vantini G, Algeri S, Curatola G, Pezzoli C, et al. Age-related modification of dopaminergic
and β-adrenergic receptor system: restoration to normal activity by modifying membrane fluidity with S-
adenosylmethionine. Life Sciences 34: 2029–2039, 1984

PubMed 
CAS 
Google Scholar 

36. Cohen BM, Satlin A, Zubenko GS. S-adenosyl-L-methionine in the treatment of Alzheimer’s disease.
Journal of Clinical Psychopharmacology 8: 43–47, 1988

PubMed 
CAS 
Google Scholar 

37. De Leo D. S-adenosyl-L-methionine (SAMe) in clinical practice: preliminary report on 75 minor

depressives. Current Therapeutic Research 37: 658–661, 1985
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 7/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

Google Scholar 

38. De Leo D. S-adenosylmethionine as an antidepressant: a double-blind trial versus placebo. Current

Therapeutic Research 41: 865–870,1987

Google Scholar 

39. Di Padova C, Di Padova F, Tritapepe R, Stramentinoli G. S-Adenosyl-L-methionine protection against

alfa-naphthyl-isothiocyanate-induced cholestasis in the rat. Toxicology Letters 29: 131–136, 1985

PubMed 
CAS 
Google Scholar 

40. Di Padova C, Tritapepe R, Di Padova F, Frezza M, Stramentinoli G. S-adenosyl-L-methionine

antagonizes oral contraceptive-induced bile cholesterol supersaturation in healthy women: preliminary
report of a controlled randomized trial. American Journal of Gastroenterology 79: 941–944, 1984a

PubMed 
Google Scholar 

41. Di Padova C, Tritapepe R, Rovagnati P, Pozzoli M, Stramentinoli G. Decreased blood levels of ethanol
and acetaldehyde by S-adenosyl-L-methionine in humans. Archives of Toxicology (Suppl. 7): 240–242,
1984b

42. Di Padova C, Vendemiale G, Marchesini G. Increased bioavailability of sulfurated compounds after S-

adenosylmethionine (SAMe) administration in alcoholics. Fourth Congress of the International Society
for Biomedical Research on Alcoholism, Kyoto, 26 June–2 July, 1988 p. 476, 1988

43. Fazio C, Andreoli V, Agnoli A, Cassachia M, Cerbo R. Effetti terapeutici e meccanismo d’azione della S-
Adenosil-L-Metionina (SAM) nelle sindromi depressive. Minerva Medica 64: 1515–1529,1973

PubMed 
CAS 
Google Scholar 

44. Fazio C, Andreoli V, Agnoli A, Casacchia M, Cerbo R, et al. Therapy of schizophrenia and depressive
disorders with S-adenosyl-L-methionine. IRCS (Research on: Clinical Pharmacology and Therapeutics;
Human Metabolism and Nutrition; Psychiatry and Clinical Psychology; Psychology) 2: 1015, 1974

Google Scholar 

45. Feo F, Pascale R, Garcea R, Daino L, Pirisi L, et al. Effect of the variations of S-adenosyl-L-methionine
liver content on fat accumulation and ethanol metabolism in ethanol-intoxicated rats. Toxicology and
Applied Pharmacology 83: 331–341, 1986

PubMed 
CAS 
Google Scholar 

46. Fiaccadori F, Frezza M, Di Padova C. Oral S-adenosylmethionine (SAMe) therapy in cholestatic patients
with chronic liver disease. Interim analysis of a placebo (P) controlled clinical trial. Journal of
Hepatology 7 (Suppl. 1): 31, 1988

Google Scholar 

47. Finkelstein JD, Kyle WE, Martin JJ, Pick A-M. Activation of cystathionine synthase by
adenosylmethionine and adenosy-lethionine. Biochemical and Research Communications 66: 81–87,
1975

CAS 
Google Scholar 

48. Frezza M, Centini G, Cammareri G, Le Grazie C, Di Padova C. S-adenosylmethionine for the treatment
of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-gastroenterology, in
press, 1989

49. Frezza M, Di Padova C. Italian Study Group for SAMe in Liver Disease. Multicenter placebo controlled
clinical trial of intravenous and oral S-adenosylmethionine (SAMe) in cholestatic patients with liver

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 8/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

disease. Abstract no. 330. Hepatology 7: 1105, 1987a

Google Scholar 

50. Frezza M, Pozzato G, Chiesa L, Stramentinoli G, Di Padova C. Reversal of intrahepatic cholestasis of

pregnancy in women after high dose S-adenosyl-L-methionine administration. Hepatology 4: 274–278,
1984

PubMed 
CAS 
Google Scholar 

51. Frezza M, Pozzato G, Pison G, Zalateo C, Chiesa L, et al. S-adenosylmethionine counteracts oral
contraceptive hepatotoxicity in women. American Journal of Medical Sciences 293: 234–238, 1987b

Google Scholar 

52. Frezza M, Tritapepe R, Pozzato G, Di Padova C. Prevention by S-adenosylmethionine of estrogen-

induced hepato biliary toxicity in susceptible women. American Journal of Gastroenterology 83: 1098–
1102, 1988

PubMed 
CAS 
Google Scholar 

53. Fricker G, Landmann L, Meier PJ. Ethinylestradiol (EE) induced structural and functional alterations of
rat liver plasma membranes and their reversal by S-adenosylmethionine (SAMe) in vitro. Abstract no. 24.
Hepatology 8: 1224, 1988

Google Scholar 

54. Gatto G, Caleri D, Michelacci S, Sicuteri F. Analgesizing effect of a methyl donor (S-adenosyl
methionine) in migraine: an open clinical trial. International Journal of Clinical Pharmacology Research
6: 15–17, 1986

PubMed 
CAS 
Google Scholar 

55. Gentile S, Persico M, Orlando C, Le Grazie C, Di Padova C, et al. Effect of different doses of S-adenosyl-
L-methionine (SAMe) on nicotinic acid-induced hyperbilirubinaemia in Gilbert’s syndrome.
Scandinavian Journal of Clinical and Laboratory Investigation 48: 525–529, 1988

PubMed 
CAS 
Google Scholar 

56. Gentile S, Persico M, Russo FS, Le Grazie C, Di Padova C, et al. Effect of S-adenosylmethionine
(SAMe) on antipyrine and rifamycin-SV half-life and serum total bibirubin in cirrhotic patients. Journal
of Hepatology, in press, 1989

57. Giannuoli G, Tine F, Malizia G, Saracco G, Verme G, et al. S-adenosylmethionine for treatment of
pruritus in compensated chronic liver disease. A pilot study. Abstract no. 24. Hepatology 6: 1110, 1986

Google Scholar 

58. Giulidori P, Cortellaro M, Moreo G, Stramentinoli G. Pharmacokinetics of S-adenosyl-L-methionine in

healthy volunteers. European Journal of Clinical Pharmacology 27: 119–121, 1984

PubMed 
CAS 
Google Scholar 

59. Giulidori P, Stramentinoli G. A radioenzymatic method for S-adenosyl-L-methionine determination in

biological fluids. Analytical Biochemistry 137: 217–220, 1984

PubMed 
CAS 
Google Scholar 

60. Hirata F, Axelrod J. Phospholipid methylation and biological signal transmission. Science 209: 1082–
1090, 1980

PubMed 
CAS 
Google Scholar 
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 9/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

61. Hirata F, Viveros OH, Diliberto EJ, Axelrod J. Identification and properties of two methyltransferases in
conversion of phosphatidylethanolamine to phosphatidylcholine. Proceedings of the National Academy of
Sciences 78: 1718–1721, 1978

Google Scholar 

62. Horowitz JH, Rypins EB, Henderson JM, Heymsfield SB, Moffitt SD, et al. Evidence for impairment of
transsulfuration pathway in cirrhosis. Gastroenterology 81: 668–675, 1981

PubMed 
CAS 
Google Scholar 

63. Ishikawa T, Sakabe T, Nishiyama Y, Abe M, Takeshita H, et al. Effect of S-adenosyl-L-methionine on

cerebral monoamine turnover after hypoxia in rats. Folia Pharmacologica Japonica 88: 425–431, 1986

PubMed 
CAS 
Google Scholar 

64. Janicak PG, Lipinski J, Davis JM, Comaty JE, Waternaux C, et al. S-adenosylmethionine in depression: a
literature review and preliminary report. Alabama Journal of Medical Sciences 25: 306–313,1988

PubMed 
CAS 
Google Scholar 

65. Kagan BL, Sultzer DL, Rosenlicht N, Gemer RH. Oral S-adenosyl-methionine in depression: a double-
blind, placebo controlled trial. Submitted to American Journal of Psychiatry for publication Küfferle B,
Grünberger J. Early clinical double-blind study with S-adenosyl-L-methionine: a new potential
antidepressant. In Costa & Racagni (Eds) Typical and atypical antidepressants: Clinical Practice, pp. 175–
180, Raven Press, New York, 1982

Google Scholar 

66. Lafuenti G, Plotti G, Nicolanti G, Caruso A, Tibollo FG, et al. Valutazione delie modificazioni di
parametri clinici e biochimici in gravide con colestasi in terapia con S-adenosyl-L-methionine per os.
Giornale Italiano di Ostetricia e Ginecologia 5: 357–361, 1988

Google Scholar 

67. Lieber CS, DeCarli IM, Kim C, Lowe N, Sasaki R, et al. S-adenosyl-L-methionine (SAMe) attenuates
alcohol-induced mitochondrial injury in the baboon. Abstract no. 773. Hepatology 8: 1412, 1988

Google Scholar 

68. Lipinski JF, Cohen BM, Frankenburg F, Tohen M, Waternaux C, et al. Open trial of S-
adenosylmethionine for treatment of depression. American Journal of Psychiatry 141: 448–450, 1984

PubMed 
CAS 
Google Scholar 

69. Loguercio C, Nardi G. Abnormal concentration of red blood cell cysteine in cirrhotics and its correction
by S-adenosylmethionine. Abstract no. 311. Journal of Hepatology 5 (Suppl. 1): 161, 1987

Google Scholar 

70. Maeda N, Kon K, Sekiya M, Shiga T. Increase of ATP level in human erythrocytes induced by S-
adenosyl-L-methionine. Biochemical Pharmacology 35: 625–629, 1986

PubMed 
CAS 
Google Scholar 

71. Manzillo G, Fiaccadori F, Frezza M, Di Padova C. Results of a placebo (P) controlled clinical trial with
oral S-adenosylmethionine (SAMe) in cholestatic patients with chronic liver disease. Abstract no; 187.
Hepatology 8: 1265, 1988

Google Scholar 

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 10/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

72. Marchesini G, Almasio P, Luca A, Maggioni Moratti E, Pisi E, et al. Sulfur amino acid (SAA) pattern in
compensated chronic liver diseases. European Journal of Clinical Investigation 19 (Part II): A94, 1989

Google Scholar 

73. Marchesini G, Bianchi GP, Lolli R, Zoli M, Pisi E. Effect of S-adenosylmethionine (SAMe) on plasma
levels of sulfur-containing amino acids (SCAA) in patients with liver cirrhosis. Journal of Hepatology 7
(Suppl. 1): 148, 1988

Google Scholar 

74. Martin Duce A, Ortiz P, Cabrero C, Mato JM. S-Adenosyl-L-methionine synthetase and phospholipid
methyltransferase are inhibited in human cirrhosis. Hepatology 8: 65–68, 1988

CAS 
Google Scholar 

75. Matsui Y, Kubo Y, Iwata N. S-Adenosyl-L-methionine prevents ischemic neuronal death. European
Journal of Pharmacology 144: 211–216, 1987

PubMed 
CAS 
Google Scholar 

76. Mazzanti R, Arcangeli A, Salvadori G, Smorlesi C, Di Perri T, et al. On the anti-steatosic effects of S-
adenosyl-L-methionine in various chronic liver diseases (multicentre study). Current Therapeutic
Research 25: 25–34, 1979

Google Scholar 

77. Mudd SM, Poole JR. Labile methyl balances for normal humans on various dietary regimes. Metabolism
24: 721–735, 1975

PubMed 
CAS 
Google Scholar 

78. Muscettola G, Galzenati M, Balbi A. SAMe versus placebo: a double blind comparison in major
depressive disorders. In Costa & Racagni (Eds) Typical and atypical antidepressants: clinical practice, pp.
151–156, Raven Press, New York, 1982

Google Scholar 

79. Nanno T, Adachi Y, Takahashi H, Yamashita M, Kobayashi H, et al. Effect of S-adenosyl-L-methionine

(SAMe) on experimental intrahepatic cholestasis. Proceedings Japan Society of Clinical Biochemistry
and Metabolism 24: 18–19, 1987

Google Scholar 

80. Ortiz P, Martin Duce A, Cabrero C. Phospholipid methylation and S-adenosylmethionine synthesis in
human liver cirrhosis. Cell Biology Reviews SI: 59–66, 1987

Google Scholar 

81. Owen JS, Bruckdorfer KR, Day RC, Mclntyre N. Decreased erythrocyte membrane fluidity and altered
lipid composition in human liver disease. Journal of Lipid Research 23: 124–132, 1982

PubMed 
CAS 
Google Scholar 

82. Paredes SR, Juknat de Geralnik AA, Batlle AM Del C, Conti HA. Beneficial effect of S-adenosyl-L-
methionine in lead intoxication. Another approach to clinical therapy. International Journal of
Biochemistry 17: 625–629, 1985a

PubMed 
CAS 
Google Scholar 

83. Paredes SR, Kozicki PA, Batlle AM Del C. S-adenosyl-L-methionine a counter to lead intoxication?
Comparative Biochem-istry and Physiology 82B: 751–757, 1985b
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 11/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

CAS 
Google Scholar 

84. Pascale R, Daino L, Garcea R, Frassetto S, Ruggiu ME, et al. Inhibition by ethanol of rat liver
plasmamembrane (Na+, K+) ATP ase. Protective effect of S-adenosyl-L-methionine, L-methionine and
N-acetylcysteine. Toxicology and Applied Pharmacology 97: 216–229, 1989

PubMed 
CAS 
Google Scholar 

85. Pezzoli C, Fiorini RM, Curatola G, Stramentinoli G. S-adenosylmethionine protects against erythrocyte
membrane alterations induced in rabbits by cholesterol-rich diet. Pharmacological Research
Communications 15: 785–795, 1983

PubMed 
CAS 
Google Scholar 

86. Pezzoli C, Kienle MG, Stramentinoli G. S-adenosylmethionine and glutathione. Submitted to

Biochemical Pharmacology for publication

87. Piccinino F, Sagnelli E, Pasquale G, Giusti G. S-adenosyl-methionine in patients with chronic active
hepatitis treated with steroids. Italian Journal of Gastroenterology 14: 186–188, 1982

Google Scholar 

88. Placidi GF, Fornaro P, Guarneri M, Stramentinoli G. Localization of S-[methyl-14C] adenosyl-L-

methionine in pregnant mice and fetuses as determined by autoradiography. European Journal of Drug
Metabolism and Pharmacokinetics No. 3: 157–161, 1979

Google Scholar 

89. Placidi GF, Stramentinoli G, Pezzoli C, Cassano GB. Distribution of S-adenosyl-L-(methyl-

14C)methionine in animals. Arzneimittel-Forschung/Drug Research 27: 1680–1684, 1977

CAS 
Google Scholar 

90. Reynolds EH, Carney MWP, Toone BK. Methylation and mood. Lancet 2: 196–198, 1984

PubMed 
CAS 
Google Scholar 

91. Reynolds EH, Carney MWP, Toone BK, Thomas CS, Edeh J, et al. Transmethylation and
neuropsychiatry. Cell Biology Reviews S1: 93–102, 1987

Google Scholar 

92. Reynolds EH, Stramentinoli G. Folic acid, S-adenosylmethionine and affective disorder. Psychological
Medicine 13: 705–710, 1983

PubMed 
CAS 
Google Scholar 

93. Rosenbaum JF, Fava M, Falk WE, Pollack MH, Cohen LS. Oral S-adenosylmethionine in major
depression. Abstract no. IOC. Presented at the 141st Annual Meeting of the American Psychiatric
Association, Montreal, 7–12 May, 1988a

94. Rosenbaum JF, Fava M, Falk WE, Pollack MH, Cohen LS, et al. An open-label pilot study of oral S-
adenosyl-L-methionine in major depression: interim results. Psychopharmacology Bulletin 24: 189–194,
1988b

PubMed 
CAS 
Google Scholar 

95. Salerno MT, Vendemiale G, Amendola A, Trione T, Palasciano G, et al. Effect of orally administered S-
adenosyl-L-methionine (SAMe) in patients with alcoholic liver disease. Abstract no. 756. Digestive
Diseases and Sciences 31 (Suppl): 192S, 1986

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 12/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

Google Scholar 

96. Salvadorini F, Galeone F, Saba P, Tognetti G, Mariani G. Evaluation of S-adenosylmethionine (SAMe)

effectiveness on depression. Current Therapeutic Research 27: 908–918, 1980

Google Scholar 

97. Sato H, Hariyama H, Moriguchi K. S-adenosyl-L-methionine protects the hippocampal CA1 neurons
from the ischemic neuronal death in rat. Biochemical and Biophysical Research Communications 150:
491–496, 1988

PubMed 
CAS 
Google Scholar 

98. Schreiber AJ, Simon FR. Estrogen-induced cholestasis: clues to pathogenesis and treatment. Hepatology
3: 607–613, 1983

PubMed 
CAS 
Google Scholar 

99. Schreiber AJ, Warren G, Sutherland E, Simon FR. S-adenosylmethionine (SAMe)-induced cytoprotection
against bile acid-induced cholestasis. Abstract. Gastroenterology 84: 1395, 1983

Google Scholar 

100. Stramentinoli G. Adomet as a drug: pharmacokinetic and pharmacological aspects. In Borchardt et al.
(Eds) Biological methylation and drug design, pp. 315–326, The Humana Press, Clifton, New Jersey,
1986a

Google Scholar 

101. Stramentinoli G. Modulation of membrane fluidity by S-adenosylmethionine treatment in different

experimental conditions. In Mato (Ed.) 1st Conference on Biochemical Pharmacological and Clinical
Aspects of Transmethylation, pp. 97–104, Spain, 1986b

Google Scholar 

102. Stramentinoli G. Various pharmacological aspects of S-adenosylmethionine: an overview. Cell Biology

Reviews S1: 67–80, 1987a

Google Scholar 

103. Stramentinoli G. Pharmacological aspects of S-adenosylmethionine: pharmacokinetics and

pharmacodynamics. American Journal of Medicine 83 (Suppl. 5A): 35–42, 1987b

PubMed 
CAS 
Google Scholar 

104. Stramentinoli G, Catto E. Pharmacokinetic studies of S-adenosyl-L-methionine (SAMe) in several animal

species. Pharmacological Research Communications 8: 211–218, 1976

PubMed 
CAS 
Google Scholar 

105. Stramentinoli G, Di Padova C, Gualano M, Royagnati P, Galli-Kienle M. Ethynylestradiol-induced

impairment of bile secretion in the rat: protective effects of S-adenosyl-L-methionine and its implication
in estrogen metabolism. Gastroenterology 80: 154–158, 1981

PubMed 
CAS 
Google Scholar 

106. Stramentinoli G, Gualano M, Galli-Kienle M. Intestinal absorption of S-adenosyl-L-methionine. Journal

of Pharmacology and Experimental Therapeutics. 209: 323–326, 1979a

PubMed 
CAS 
Google Scholar 

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 13/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

107. Stramentinoli G, Pezzoli C, Galli-Kienle M. Protective role of S-adenosyl-L-methionine against

acetaminophen induced mortality and hepatotoxicity in mice. Biochemical Pharmacology 28: 3567–3571,
1979b

PubMed 
CAS 
Google Scholar 

108. Takahashi J, Nishino H, Ono T. Effect of S-adenosyl-L-methionine (SAMe) on disturbances in hand

movement and delayed response tasks after lesion of motor or prefrontal cortex in the monkey. Folia
Pharmacologica Japonica 87: 507–519, 1986

PubMed 
CAS 
Google Scholar 

109. Tavoni A, Vitali C, Bombardieri S, Pasero G. Evaluation of S-adenosylmethionine in primary

fibromyalgia: a double-blind crossover study. American Journal of Medicine 83 (Suppl. 5A): 107–110,
1987

PubMed 
CAS 
Google Scholar 

110. Tolbert LC. MAT kinetics in affective disorders; and schizophrenia: an account. Alabama Journal of
Medical Sciences 25: 291–296, 1988

PubMed 
CAS 
Google Scholar 

111. Torta R, Zanalda E, Rocca P, Ravizza L. Inhibitory activity of S-adenosyl-L-methionine on serum

gamma-glutamyl-transpep-tidase increase induced by psychodrugs and anticonvulsants. Current
Therapeutic Research 44: 144–159, 1988

Google Scholar 

112. Trovarelli G, De Medio GE, Porcellati S, Stramentinoli G, Porcellati G. The effect of S-adenosyl-L-
methionine on ischemia-induced disturbances of brain phospholipid in the gerbil. Neurochemical
Research 8: 1597–1609, 1983

PubMed 
CAS 
Google Scholar 

113. Vendemiale G, Altomare E, Altavilla R, Le Grazie C, Di Padova C, et al. S-adenosylmethionine (SAMe)

improves acetaminophen metabolism in cirrhotic patients. Journal of Hepatology, in press, 1989b

114. Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, et al. Effects of oral S-adenosyl-L-
methionine on hepatic glutathione in patients with liver disease. Scandinavian Journal of
Gastroenterology, in press, 1989a

115. Vendemiale G, Altomare E, Trizio T, Salerno MT, Stufano N, et al. Effect of S-adenosyl-L-methionine on
hepatic glutathione in patients with liver injury. Abstract 358. Digestive Diseases and Sciences 31
(Suppl.): 92, 1986

Google Scholar 

116. Vore M. Estrogen cholestasis. Membranes, metabolites, or receptors? Gastroenterology 93: 643–647,
1987

PubMed 
CAS 
Google Scholar 

117. Yousef IM, Barnwell SG, Tuchweber B, Weber A, Roy CC. Effect of complete sulfation of bile acids on
bile formation in rats. Hepatology 7: 535–542, 1987

PubMed 
CAS 
Google Scholar 

118. Zeisel SM, Poole JR. Dietary intake of methionine: influence on brain S-adenosylmethionine. In Usdin E,
Boechardt RT, Greveling CR (Eds) Transmethylation, pp 59–68, Elsevier/North-Holland, The
Netherlands, 1979

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 14/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

Google Scholar 

Download references

Author information
Affiliations

1. ADIS Drug Information Services, Auckland, New Zealand

Heather A. Friedel, Karen L. Goa & Paul Benfield

Authors

1. Heather A. Friedel
View author publications

You can also search for this author in

PubMed Google Scholar

2. Karen L. Goa
View author publications

You can also search for this author in

PubMed Google Scholar

3. Paul Benfield
View author publications

You can also search for this author in

PubMed Google Scholar

Corresponding author

Correspondence to
Heather A. Friedel.

Additional information
Various sections of the manuscript reviewed by: E. Alvarez, Department of Psychiatry, School of Medicine,
Sant Pau Hospital, Barcelona, Spain; I. Caruso, Department of Rheumatology, L. Sacco Hospital, Milan, Italy;
P.K. Chiang, Division of Biochemistry, Walter Reed Army Institute of Research, Washington DC, USA: M.
Frezza, Institute of Medical Pathology; University of Trieste, Trieste, Italy; D.E. Furst, Department of
Medicine, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA: M.H.
Lader, Institute of Psychiatry; University of London, London, England; J.M. Mato, Departamento de
Metabolismo, Nutrition y Hormonas, Fundación Jiménez Diaz, Madrid, Spain; S. Montgomery, Academic
Department of Psychiatry, St Mary’s Hospital Medical School, London, England; E.H. Reynolds, King’s
College Hospital, London, England; M. Tanaka, Department of Pharmacology, Kurume University School of
Medicine, Kurume, Japan; G.C. Weir, Joslin Diabetes Center, Boston, Massachusetts, USA: R.L. Williams, The
Drug Studies Unit, University of California, San Francisco, California, USA.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 15/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

Friedel, H.A., Goa, K.L. & Benfield, P. S-Adenosyl-L-Methionine.

Drugs 38, 389–416 (1989).
https://doi.org/10.2165/00003495-198938030-00004

Download citation

Published: 27 October 2012

Issue Date: September 1989

DOI: https://doi.org/10.2165/00003495-198938030-00004

Keywords
Taurine
Chronic Liver Disease
Cholestasis
Clomipramine
Lead Poisoning

Access options

Buy article PDF

39,95 €
Price includes VAT (India)

Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Rent this article via DeepDyve.

Learn more about Institutional subscriptions

Sections
References

Summary
References
Author information
Additional information
Rights and permissions
About this article

Advertisement

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 16/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

1. Adachi Y, Nanno T, Kanbe A, Inufusa H, Yamashita

M, et al. The effects of S-adenosylmethionine on
intrahepatic cholestasis. Japanese Archives of
Internal Medicine 33: 185–192, 1986

Google Scholar 

2. Agnoli A, Andreoli V, Casacchia M, Cerbo R. Effect

of S-adenosyl-L-methionine (SAMe) upon
depressive symptoms. Journal of Psychiatric
Research 13: 43–54, 1976

PubMed CAS 
Google Scholar 

3. Agnoli A, Martucci N, Manna V. On the

antidepressant effect of SAMe: clinical and
pharmaco-EEG study with SAMe alone and in
association with a beta-2 stimulant drug, phenoterole.
Clinical Neuropharmacology 7 (Suppl. 1): 104–105,
1984

Google Scholar 

4. Altomare E, Vendemiale G, Marchesini G, Le Grazie

C, Di Padova C. Increased bioavailability of
sulfurated compounds after S-adenosylmethionine
(SAMe) administration to alcoholics. In Kuriyama et
al. (Eds) Biomedical and social aspects of alcohol
and alcoholism, pp. 353–356, Elsevier Science
Publishers B.V., 1988

Google Scholar 

5. Alvarez E. SAMe and depression. In Mato (Ed.) 1st

Conference on biomedical pharmacological and
clinical aspects of transmethylation, pp. 107–114,
Spain, 1986

Google Scholar 

6. Alvarez E, Udina C, Guillamat R. Shortening of

latency period in depressed patients treated with
SAM and other antidepressant drugs. Cell Biology
Reviews S1: 103–110, 1987

Google Scholar 
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 17/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

7. Andreoli V, Campedelli A, Maffei F. La S-adenosil-

L-metionina (SAMe) in geropsichiatria: uno studio
clinico controllato « in a perto » nelle sindromi
depressive dell’eta senile. Giornale di Gerontologia
25: 172–180, 1977

Google Scholar 

8. Arias IM. Ion transport into and out of the liver. In

Keppler D, Popper H, Bianchi L, et al. (Eds)
Mechanisms of hepatocyte injury and death, pp 49–
56, MTP Press, Lancaster, UK, 1983

Google Scholar 

9. Arias IM. Mechanisms and consequences of ion

transport in the liver. In Popper H, Schaffner F (Eds)
Progress in liver diseases, vol. III, pp. 145–159,
Grune & Stratton Inc, Orlando, USA, 1986

Google Scholar 

10. Artale F, Francisci A, Espureo M, Sergio G,

Cramarossa L, et al. Effects of S-adenosyl-L-
methionine on hemorheological changes induced by
exercise in patients with peripheral occlusive arterial
diseases. Current Therapeutic Research 32: 520–528,
1982

Google Scholar 

11. Baldessarini RJ. Neuropharmacology of S-adenosyl-

L-methionine. American Journal of Medicine 83
(Suppl. 5A): 95–103, 1987

PubMed CAS 
Google Scholar 

12. Baldessarini RJ, Kopin IJ. S-Adenosyl-L-methionine

in brain and other tissues. Journal of Neurochemistry
13: 769–777, 1966

PubMed CAS 
Google Scholar 

13. Barber JR, Morimoto BH, Brunauer LS, Clarke S.

Metabolism of S-adenosyl-L-methionine in intact
human erythrocytes. Biochimica et Biophysica Acta
887: 361–372, 1986

Google Scholar 

14. Batlle AM Del C, Paredes SR, Fukuda H, Kozicki

PA, Rossetti MV. S-adenosyl-L-methionine, a
mechanism for its action on lead mobilisation and
disposal in lead poisoning. Biochemical Archives 2:
293–303, 1986

Google Scholar 

15. Batlle AM Del C, Stella AM, De Kaminsky AR,

Kaminsky C, Mariano HG. Two cases of infantile
porphyria cutanea tarda: successful treatment with
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 18/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

oral S-adenosyl-L-methionine and low-dose oral

chloroquine. British Journal of Dermatology 116:
407–415, 1987

Google Scholar 

16. Bell KM, Plon L, Bunney Jr WE, Potkin SG. S-

adenosylmethionine treatment of depression: a
controlled clinical trial. American Journal of
Psychiatry 145: 1110–1114, 1988

PubMed CAS 
Google Scholar 

17. Berger R, Nowak H. A new medical approach to the

treatment of osteoarthritis: report of an open phase
IV study with ademetionine (Gumbaral). American
Journal of Medicine 83 (Suppl. 5A): 84–88, 1987

PubMed CAS 
Google Scholar 

18. Boelsterli UA, Rakhit G, Balazs T. Modulation by S-

adenosyl-L-methionine of hepatic Na+, K+-ATPase,
membrane fluidity, and bile flow in rats with ethinyl
estradiol-induced cholestasis. Hepatology 3: 12–17,
1983

PubMed CAS 
Google Scholar 

19. Bombardieri G, Milani A, Bernardi L, Rossi L.

Effects of S-ad-enosyl-methionine (SAMe) in the
treatment of Gilbert’s syndrome. Current Therapeutic
Research 37: 580–585, 1985

Google Scholar 

20. Bombardieri G, Pappalardo G, Bernardi L, Barra D,

Di Palma A, et al. Intestinal absorption of S-
adenosyl-L-methionine in humans. International
Journal of Clinical Pharmacology, Therapy and
Toxicology 21: 186–188, 1983

CAS 
Google Scholar 

21. Bottiglieri T, Chary TK, Laundy M, Carney MWP,

Godfrey P, et al. Transmethylation in depression.
Alabama Journal of Medical Sciences 25: 296–301,
1988

PubMed CAS 
Google Scholar 

22. Bottiglieri T, Laundy M, Martin R, Carney MWP,

Nissenbaum H, et al. S-adenosyl-methionine
influences monoamine metabolism. Lancet 2: 224,
1984

PubMed CAS 
Google Scholar 

23. Burk RF. Hepatocytoprotective substances.

Gastroenterology 81: 397–398, 1981

PubMed CAS 
Google Scholar 
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 19/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

24. Cabrero C, Martin Duce A, Ortiz P, Alemany S,

Mato JM. Specific loss of the high-molecular-weight
form of S-adenosyl-L-methionine synthetase in
human liver cirrhosis. Hepatology 88: 1530–1534,
1988

Google Scholar 

25. Cacciatore L, Cozzolino G, Varriale A, Dionisio M.

Treatment of pruritus in chronic liver disease with S-
adenosylmethionine. European Journal of Clinical
Investigation 19 (Part II): A15, 1989

Google Scholar 

26. Carney MWP. Review. Neuropharmacology of S-

adenosylmethionine. Clinical Neuropharmacology 9:
235–243, 1986

PubMed CAS 
Google Scholar 

27. Carney MWP, Chary TKN, Bottiglieri T. Switch

mechanism in affective illness and oral S-
adenosylmethionine (SAM). British Journal of
Psychiatry 150: 724–725, 1987

PubMed CAS 
Google Scholar 

28. Carney MWP, Chary TKN, Bottiglieri T, Reynolds

EH. Switch and S-adenosyl-methionine. Alabama
Journal of Medical Sciences 25: 316–319, 1988

PubMed CAS 
Google Scholar 

29. Carney MWP, Martin R, Bottiglieri T, Reynolds EH,

Nissenbaum H, et al. Switch mechanism in affective
illness and S-adenosylmethionine. Lancet 1: 820–
821, 1983

PubMed CAS 
Google Scholar 

30. Carney MWP, Edeh J, Bottiglieri T, Reynolds EM,

Toone BK. Affective illness and S-
adenosylmethionine: a preliminary report. Clinical
Neuropharmacology 9: 379–385, 1986

PubMed CAS 
Google Scholar 

31. Caruso I, Fumagalli M, Boccassini L, Sarzi Puttini P,

Santandrea S, et al. Treatment of depression in
rheumatoid arthritic patients: a comparison of S-
adenosylmethionine (Samyr®) and placebo in a
double-blind study. Clinical Trials Journal 24: 305–
310, 1987

Google Scholar 

32. Celani T, Iorio G, Vacca L, Amati A, Del Vecchio M.

Electroen-cephalographic control with frequency
analysis in depressed patients treated with SAMe.
Current Therapeutic Research 23: 525–527, 1978
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 20/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

Google Scholar 

33. Chawla RK, Lewis FW, Kutner MH, Bate DM, Roy
RGB et al. Plasma cysteine, cystine, and glutathione
in cirrhosis. Gastroenterology 87: 770–776, 1984

PubMed CAS 
Google Scholar 

34. Cibin M, Gentile N, Ferri M, Canton G, Gallimberti

L. S-adenosylmethionine (SAMe) is effective in
reducing ethanol abuse in an outpatient program for
alcoholics. In Kuriyama et al. (Eds) Biomedical and
social aspects of alcohol and alcoholism, pp. 357–
360, Elsevier Science Publishers B.V., 1988

Google Scholar 

35. Cimino M, Vantini G, Algeri S, Curatola G, Pezzoli

C, et al. Age-related modification of dopaminergic
and β-adrenergic receptor system: restoration to
normal activity by modifying membrane fluidity with
S-adenosylmethionine. Life Sciences 34: 2029–2039,
1984

PubMed CAS 
Google Scholar 

36. Cohen BM, Satlin A, Zubenko GS. S-adenosyl-L-

methionine in the treatment of Alzheimer’s disease.
Journal of Clinical Psychopharmacology 8: 43–47,
1988

PubMed CAS 
Google Scholar 

37. De Leo D. S-adenosyl-L-methionine (SAMe) in

clinical practice: preliminary report on 75 minor
depressives. Current Therapeutic Research 37: 658–
661, 1985

Google Scholar 

38. De Leo D. S-adenosylmethionine as an

antidepressant: a double-blind trial versus placebo.
Current Therapeutic Research 41: 865–870,1987

Google Scholar 

39. Di Padova C, Di Padova F, Tritapepe R,

Stramentinoli G. S-Adenosyl-L-methionine
protection against alfa-naphthyl-isothiocyanate-
induced cholestasis in the rat. Toxicology Letters 29:
131–136, 1985

PubMed CAS 
Google Scholar 

40. Di Padova C, Tritapepe R, Di Padova F, Frezza M,

Stramentinoli G. S-adenosyl-L-methionine
antagonizes oral contraceptive-induced bile
cholesterol supersaturation in healthy women:
preliminary report of a controlled randomized trial.
American Journal of Gastroenterology 79: 941–944,
1984a
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 21/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

PubMed 
Google Scholar 

41. Di Padova C, Tritapepe R, Rovagnati P, Pozzoli M,

Stramentinoli G. Decreased blood levels of ethanol
and acetaldehyde by S-adenosyl-L-methionine in
humans. Archives of Toxicology (Suppl. 7): 240–
242, 1984b

42. Di Padova C, Vendemiale G, Marchesini G.

Increased bioavailability of sulfurated compounds
after S-adenosylmethionine (SAMe) administration
in alcoholics. Fourth Congress of the International
Society for Biomedical Research on Alcoholism,
Kyoto, 26 June–2 July, 1988 p. 476, 1988

43. Fazio C, Andreoli V, Agnoli A, Cassachia M, Cerbo

R. Effetti terapeutici e meccanismo d’azione della S-
Adenosil-L-Metionina (SAM) nelle sindromi
depressive. Minerva Medica 64: 1515–1529,1973

PubMed CAS 
Google Scholar 

44. Fazio C, Andreoli V, Agnoli A, Casacchia M, Cerbo

R, et al. Therapy of schizophrenia and depressive
disorders with S-adenosyl-L-methionine. IRCS
(Research on: Clinical Pharmacology and
Therapeutics; Human Metabolism and Nutrition;
Psychiatry and Clinical Psychology; Psychology) 2:
1015, 1974

Google Scholar 

45. Feo F, Pascale R, Garcea R, Daino L, Pirisi L, et al.

Effect of the variations of S-adenosyl-L-methionine
liver content on fat accumulation and ethanol
metabolism in ethanol-intoxicated rats. Toxicology
and Applied Pharmacology 83: 331–341, 1986

PubMed CAS 
Google Scholar 

46. Fiaccadori F, Frezza M, Di Padova C. Oral S-

adenosylmethionine (SAMe) therapy in cholestatic
patients with chronic liver disease. Interim analysis
of a placebo (P) controlled clinical trial. Journal of
Hepatology 7 (Suppl. 1): 31, 1988

Google Scholar 

47. Finkelstein JD, Kyle WE, Martin JJ, Pick A-M.

Activation of cystathionine synthase by
adenosylmethionine and adenosy-lethionine.
Biochemical and Research Communications 66: 81–
87, 1975

CAS 
Google Scholar 

48. Frezza M, Centini G, Cammareri G, Le Grazie C, Di

Padova C. S-adenosylmethionine for the treatment of
intrahepatic cholestasis of pregnancy. Results of a
controlled clinical trial. Hepato-gastroenterology, in
press, 1989
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 22/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

49. Frezza M, Di Padova C. Italian Study Group for

SAMe in Liver Disease. Multicenter placebo
controlled clinical trial of intravenous and oral S-
adenosylmethionine (SAMe) in cholestatic patients
with liver disease. Abstract no. 330. Hepatology 7:
1105, 1987a

Google Scholar 

50. Frezza M, Pozzato G, Chiesa L, Stramentinoli G, Di

Padova C. Reversal of intrahepatic cholestasis of
pregnancy in women after high dose S-adenosyl-L-
methionine administration. Hepatology 4: 274–278,
1984

PubMed CAS 
Google Scholar 

51. Frezza M, Pozzato G, Pison G, Zalateo C, Chiesa L,

et al. S-adenosylmethionine counteracts oral
contraceptive hepatotoxicity in women. American
Journal of Medical Sciences 293: 234–238, 1987b

Google Scholar 

52. Frezza M, Tritapepe R, Pozzato G, Di Padova C.

Prevention by S-adenosylmethionine of estrogen-
induced hepato biliary toxicity in susceptible women.
American Journal of Gastroenterology 83: 1098–
1102, 1988

PubMed CAS 
Google Scholar 

53. Fricker G, Landmann L, Meier PJ. Ethinylestradiol

(EE) induced structural and functional alterations of
rat liver plasma membranes and their reversal by S-
adenosylmethionine (SAMe) in vitro. Abstract no.
24. Hepatology 8: 1224, 1988

Google Scholar 

54. Gatto G, Caleri D, Michelacci S, Sicuteri F.

Analgesizing effect of a methyl donor (S-adenosyl
methionine) in migraine: an open clinical trial.
International Journal of Clinical Pharmacology
Research 6: 15–17, 1986

PubMed CAS 
Google Scholar 

55. Gentile S, Persico M, Orlando C, Le Grazie C, Di

Padova C, et al. Effect of different doses of S-
adenosyl-L-methionine (SAMe) on nicotinic acid-
induced hyperbilirubinaemia in Gilbert’s syndrome.
Scandinavian Journal of Clinical and Laboratory
Investigation 48: 525–529, 1988

PubMed CAS 
Google Scholar 

56. Gentile S, Persico M, Russo FS, Le Grazie C, Di

Padova C, et al. Effect of S-adenosylmethionine
(SAMe) on antipyrine and rifamycin-SV half-life and

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 23/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

serum total bibirubin in cirrhotic patients. Journal of

Hepatology, in press, 1989

57. Giannuoli G, Tine F, Malizia G, Saracco G, Verme G,

et al. S-adenosylmethionine for treatment of pruritus
in compensated chronic liver disease. A pilot study.
Abstract no. 24. Hepatology 6: 1110, 1986

Google Scholar 

58. Giulidori P, Cortellaro M, Moreo G, Stramentinoli G.

Pharmacokinetics of S-adenosyl-L-methionine in
healthy volunteers. European Journal of Clinical
Pharmacology 27: 119–121, 1984

PubMed CAS 
Google Scholar 

59. Giulidori P, Stramentinoli G. A radioenzymatic

method for S-adenosyl-L-methionine determination
in biological fluids. Analytical Biochemistry 137:
217–220, 1984

PubMed CAS 
Google Scholar 

60. Hirata F, Axelrod J. Phospholipid methylation and

biological signal transmission. Science 209: 1082–
1090, 1980

PubMed CAS 
Google Scholar 

61. Hirata F, Viveros OH, Diliberto EJ, Axelrod J.

Identification and properties of two
methyltransferases in conversion of
phosphatidylethanolamine to phosphatidylcholine.
Proceedings of the National Academy of Sciences
78: 1718–1721, 1978

Google Scholar 

62. Horowitz JH, Rypins EB, Henderson JM, Heymsfield

SB, Moffitt SD, et al. Evidence for impairment of
transsulfuration pathway in cirrhosis.
Gastroenterology 81: 668–675, 1981

PubMed CAS 
Google Scholar 

63. Ishikawa T, Sakabe T, Nishiyama Y, Abe M,

Takeshita H, et al. Effect of S-adenosyl-L-methionine
on cerebral monoamine turnover after hypoxia in
rats. Folia Pharmacologica Japonica 88: 425–431,
1986

PubMed CAS 
Google Scholar 

64. Janicak PG, Lipinski J, Davis JM, Comaty JE,

Waternaux C, et al. S-adenosylmethionine in
depression: a literature review and preliminary
report. Alabama Journal of Medical Sciences 25:
306–313,1988

PubMed CAS 
Google Scholar 
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 24/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

65. Kagan BL, Sultzer DL, Rosenlicht N, Gemer RH.

Oral S-adenosyl-methionine in depression: a double-
blind, placebo controlled trial. Submitted to
American Journal of Psychiatry for publication
Küfferle B, Grünberger J. Early clinical double-blind
study with S-adenosyl-L-methionine: a new potential
antidepressant. In Costa & Racagni (Eds) Typical and
atypical antidepressants: Clinical Practice, pp. 175–
180, Raven Press, New York, 1982

Google Scholar 

66. Lafuenti G, Plotti G, Nicolanti G, Caruso A, Tibollo

FG, et al. Valutazione delie modificazioni di
parametri clinici e biochimici in gravide con colestasi
in terapia con S-adenosyl-L-methionine per os.
Giornale Italiano di Ostetricia e Ginecologia 5: 357–
361, 1988

Google Scholar 

67. Lieber CS, DeCarli IM, Kim C, Lowe N, Sasaki R, et

al. S-adenosyl-L-methionine (SAMe) attenuates
alcohol-induced mitochondrial injury in the baboon.
Abstract no. 773. Hepatology 8: 1412, 1988

Google Scholar 

68. Lipinski JF, Cohen BM, Frankenburg F, Tohen M,

Waternaux C, et al. Open trial of S-
adenosylmethionine for treatment of depression.
American Journal of Psychiatry 141: 448–450, 1984

PubMed CAS 
Google Scholar 

69. Loguercio C, Nardi G. Abnormal concentration of

red blood cell cysteine in cirrhotics and its correction
by S-adenosylmethionine. Abstract no. 311. Journal
of Hepatology 5 (Suppl. 1): 161, 1987

Google Scholar 

70. Maeda N, Kon K, Sekiya M, Shiga T. Increase of

ATP level in human erythrocytes induced by S-
adenosyl-L-methionine. Biochemical Pharmacology
35: 625–629, 1986

PubMed CAS 
Google Scholar 

71. Manzillo G, Fiaccadori F, Frezza M, Di Padova C.

Results of a placebo (P) controlled clinical trial with
oral S-adenosylmethionine (SAMe) in cholestatic
patients with chronic liver disease. Abstract no; 187.
Hepatology 8: 1265, 1988

Google Scholar 

72. Marchesini G, Almasio P, Luca A, Maggioni Moratti

E, Pisi E, et al. Sulfur amino acid (SAA) pattern in
compensated chronic liver diseases. European

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 25/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

Journal of Clinical Investigation 19 (Part II): A94,

1989

Google Scholar 

73. Marchesini G, Bianchi GP, Lolli R, Zoli M, Pisi E.

Effect of S-adenosylmethionine (SAMe) on plasma
levels of sulfur-containing amino acids (SCAA) in
patients with liver cirrhosis. Journal of Hepatology 7
(Suppl. 1): 148, 1988

Google Scholar 

74. Martin Duce A, Ortiz P, Cabrero C, Mato JM. S-

Adenosyl-L-methionine synthetase and phospholipid
methyltransferase are inhibited in human cirrhosis.
Hepatology 8: 65–68, 1988

CAS 
Google Scholar 

75. Matsui Y, Kubo Y, Iwata N. S-Adenosyl-L-

methionine prevents ischemic neuronal death.
European Journal of Pharmacology 144: 211–216,
1987

PubMed CAS 
Google Scholar 

76. Mazzanti R, Arcangeli A, Salvadori G, Smorlesi C,

Di Perri T, et al. On the anti-steatosic effects of S-
adenosyl-L-methionine in various chronic liver
diseases (multicentre study). Current Therapeutic
Research 25: 25–34, 1979

Google Scholar 

77. Mudd SM, Poole JR. Labile methyl balances for

normal humans on various dietary regimes.
Metabolism 24: 721–735, 1975

PubMed CAS 
Google Scholar 

78. Muscettola G, Galzenati M, Balbi A. SAMe versus

placebo: a double blind comparison in major
depressive disorders. In Costa & Racagni (Eds)
Typical and atypical antidepressants: clinical
practice, pp. 151–156, Raven Press, New York, 1982

Google Scholar 

79. Nanno T, Adachi Y, Takahashi H, Yamashita M,

Kobayashi H, et al. Effect of S-adenosyl-L-
methionine (SAMe) on experimental intrahepatic
cholestasis. Proceedings Japan Society of Clinical
Biochemistry and Metabolism 24: 18–19, 1987

Google Scholar 

80. Ortiz P, Martin Duce A, Cabrero C. Phospholipid

methylation and S-adenosylmethionine synthesis in
human liver cirrhosis. Cell Biology Reviews SI: 59–
66, 1987
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 26/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

Google Scholar 

81. Owen JS, Bruckdorfer KR, Day RC, Mclntyre N.

Decreased erythrocyte membrane fluidity and altered
lipid composition in human liver disease. Journal of
Lipid Research 23: 124–132, 1982

PubMed CAS 
Google Scholar 

82. Paredes SR, Juknat de Geralnik AA, Batlle AM Del

C, Conti HA. Beneficial effect of S-adenosyl-L-
methionine in lead intoxication. Another approach to
clinical therapy. International Journal of
Biochemistry 17: 625–629, 1985a

PubMed CAS 
Google Scholar 

83. Paredes SR, Kozicki PA, Batlle AM Del C. S-

adenosyl-L-methionine a counter to lead
intoxication? Comparative Biochem-istry and
Physiology 82B: 751–757, 1985b

CAS 
Google Scholar 

84. Pascale R, Daino L, Garcea R, Frassetto S, Ruggiu

ME, et al. Inhibition by ethanol of rat liver
plasmamembrane (Na+, K+) ATP ase. Protective
effect of S-adenosyl-L-methionine, L-methionine and
N-acetylcysteine. Toxicology and Applied
Pharmacology 97: 216–229, 1989

PubMed CAS 
Google Scholar 

85. Pezzoli C, Fiorini RM, Curatola G, Stramentinoli G.

S-adenosylmethionine protects against erythrocyte
membrane alterations induced in rabbits by
cholesterol-rich diet. Pharmacological Research
Communications 15: 785–795, 1983

PubMed CAS 
Google Scholar 

86. Pezzoli C, Kienle MG, Stramentinoli G. S-

adenosylmethionine and glutathione. Submitted to
Biochemical Pharmacology for publication

87. Piccinino F, Sagnelli E, Pasquale G, Giusti G. S-

adenosyl-methionine in patients with chronic active
hepatitis treated with steroids. Italian Journal of
Gastroenterology 14: 186–188, 1982

Google Scholar 

88. Placidi GF, Fornaro P, Guarneri M, Stramentinoli G.

Localization of S-[methyl-14C] adenosyl-L-
methionine in pregnant mice and fetuses as
determined by autoradiography. European Journal of
Drug Metabolism and Pharmacokinetics No. 3: 157–
161, 1979

Google Scholar 

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 27/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

89. Placidi GF, Stramentinoli G, Pezzoli C, Cassano GB.

Distribution of S-adenosyl-L-(methyl-
14C)methionine in animals. Arzneimittel-
Forschung/Drug Research 27: 1680–1684, 1977

CAS 
Google Scholar 

90. Reynolds EH, Carney MWP, Toone BK. Methylation

and mood. Lancet 2: 196–198, 1984

PubMed CAS 
Google Scholar 

91. Reynolds EH, Carney MWP, Toone BK, Thomas CS,

Edeh J, et al. Transmethylation and neuropsychiatry.
Cell Biology Reviews S1: 93–102, 1987

Google Scholar 

92. Reynolds EH, Stramentinoli G. Folic acid, S-

adenosylmethionine and affective disorder.
Psychological Medicine 13: 705–710, 1983

PubMed CAS 
Google Scholar 

93. Rosenbaum JF, Fava M, Falk WE, Pollack MH,

Cohen LS. Oral S-adenosylmethionine in major
depression. Abstract no. IOC. Presented at the 141st
Annual Meeting of the American Psychiatric
Association, Montreal, 7–12 May, 1988a

94. Rosenbaum JF, Fava M, Falk WE, Pollack MH,

Cohen LS, et al. An open-label pilot study of oral S-
adenosyl-L-methionine in major depression: interim
results. Psychopharmacology Bulletin 24: 189–194,
1988b

PubMed CAS 
Google Scholar 

95. Salerno MT, Vendemiale G, Amendola A, Trione T,

Palasciano G, et al. Effect of orally administered S-
adenosyl-L-methionine (SAMe) in patients with
alcoholic liver disease. Abstract no. 756. Digestive
Diseases and Sciences 31 (Suppl): 192S, 1986

Google Scholar 

96. Salvadorini F, Galeone F, Saba P, Tognetti G, Mariani

G. Evaluation of S-adenosylmethionine (SAMe)
effectiveness on depression. Current Therapeutic
Research 27: 908–918, 1980

Google Scholar 

97. Sato H, Hariyama H, Moriguchi K. S-adenosyl-L-

methionine protects the hippocampal CA1 neurons
from the ischemic neuronal death in rat. Biochemical
and Biophysical Research Communications 150:
491–496, 1988

PubMed CAS 
Google Scholar 

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 28/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

98. Schreiber AJ, Simon FR. Estrogen-induced

cholestasis: clues to pathogenesis and treatment.
Hepatology 3: 607–613, 1983

PubMed CAS 
Google Scholar 

99. Schreiber AJ, Warren G, Sutherland E, Simon FR. S-

adenosylmethionine (SAMe)-induced cytoprotection
against bile acid-induced cholestasis. Abstract.
Gastroenterology 84: 1395, 1983

Google Scholar 

100. Stramentinoli G. Adomet as a drug: pharmacokinetic

and pharmacological aspects. In Borchardt et al.
(Eds) Biological methylation and drug design, pp.
315–326, The Humana Press, Clifton, New Jersey,
1986a

Google Scholar 

101. Stramentinoli G. Modulation of membrane fluidity

by S-adenosylmethionine treatment in different
experimental conditions. In Mato (Ed.) 1st
Conference on Biochemical Pharmacological and
Clinical Aspects of Transmethylation, pp. 97–104,
Spain, 1986b

Google Scholar 

102. Stramentinoli G. Various pharmacological aspects of

S-adenosylmethionine: an overview. Cell Biology
Reviews S1: 67–80, 1987a

Google Scholar 

103. Stramentinoli G. Pharmacological aspects of S-

adenosylmethionine: pharmacokinetics and
pharmacodynamics. American Journal of Medicine
83 (Suppl. 5A): 35–42, 1987b

PubMed CAS 
Google Scholar 

104. Stramentinoli G, Catto E. Pharmacokinetic studies of

S-adenosyl-L-methionine (SAMe) in several animal
species. Pharmacological Research Communications
8: 211–218, 1976

PubMed CAS 
Google Scholar 

105. Stramentinoli G, Di Padova C, Gualano M,

Royagnati P, Galli-Kienle M. Ethynylestradiol-
induced impairment of bile secretion in the rat:
protective effects of S-adenosyl-L-methionine and its
implication in estrogen metabolism.
Gastroenterology 80: 154–158, 1981

PubMed CAS 
Google Scholar 

106. Stramentinoli G, Gualano M, Galli-Kienle M.

Intestinal absorption of S-adenosyl-L-methionine.
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 29/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

Journal of Pharmacology and Experimental

Therapeutics. 209: 323–326, 1979a

PubMed CAS 
Google Scholar 

107. Stramentinoli G, Pezzoli C, Galli-Kienle M.

Protective role of S-adenosyl-L-methionine against
acetaminophen induced mortality and hepatotoxicity
in mice. Biochemical Pharmacology 28: 3567–3571,
1979b

PubMed CAS 
Google Scholar 

108. Takahashi J, Nishino H, Ono T. Effect of S-adenosyl-

L-methionine (SAMe) on disturbances in hand
movement and delayed response tasks after lesion of
motor or prefrontal cortex in the monkey. Folia
Pharmacologica Japonica 87: 507–519, 1986

PubMed CAS 
Google Scholar 

109. Tavoni A, Vitali C, Bombardieri S, Pasero G.

Evaluation of S-adenosylmethionine in primary
fibromyalgia: a double-blind crossover study.
American Journal of Medicine 83 (Suppl. 5A): 107–
110, 1987

PubMed CAS 
Google Scholar 

110. Tolbert LC. MAT kinetics in affective disorders; and

schizophrenia: an account. Alabama Journal of
Medical Sciences 25: 291–296, 1988

PubMed CAS 
Google Scholar 

111. Torta R, Zanalda E, Rocca P, Ravizza L. Inhibitory

activity of S-adenosyl-L-methionine on serum
gamma-glutamyl-transpep-tidase increase induced by
psychodrugs and anticonvulsants. Current
Therapeutic Research 44: 144–159, 1988

Google Scholar 

112. Trovarelli G, De Medio GE, Porcellati S,

Stramentinoli G, Porcellati G. The effect of S-
adenosyl-L-methionine on ischemia-induced
disturbances of brain phospholipid in the gerbil.
Neurochemical Research 8: 1597–1609, 1983

PubMed CAS 
Google Scholar 

113. Vendemiale G, Altomare E, Altavilla R, Le Grazie C,

Di Padova C, et al. S-adenosylmethionine (SAMe)
improves acetaminophen metabolism in cirrhotic
patients. Journal of Hepatology, in press, 1989b

114. Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di

Padova C, et al. Effects of oral S-adenosyl-L-
methionine on hepatic glutathione in patients with
liver disease. Scandinavian Journal of
Gastroenterology, in press, 1989a
https://link.springer.com/article/10.2165%2F00003495-198938030-00004 30/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

115. Vendemiale G, Altomare E, Trizio T, Salerno MT,

Stufano N, et al. Effect of S-adenosyl-L-methionine
on hepatic glutathione in patients with liver injury.
Abstract 358. Digestive Diseases and Sciences 31
(Suppl.): 92, 1986

Google Scholar 

116. Vore M. Estrogen cholestasis. Membranes,

metabolites, or receptors? Gastroenterology 93: 643–
647, 1987

PubMed CAS 
Google Scholar 

117. Yousef IM, Barnwell SG, Tuchweber B, Weber A,

Roy CC. Effect of complete sulfation of bile acids on
bile formation in rats. Hepatology 7: 535–542, 1987

PubMed CAS 
Google Scholar 

118. Zeisel SM, Poole JR. Dietary intake of methionine:

influence on brain S-adenosylmethionine. In Usdin
E, Boechardt RT, Greveling CR (Eds)
Transmethylation, pp 59–68, Elsevier/North-Holland,
The Netherlands, 1979

Google Scholar 

Over 10 million scientific documents at your fingertips

Switch Edition

Academic Edition
Corporate Edition

Home
Impressum
Legal information
Privacy statement
California Privacy Statement
How we use cookies
Manage cookies/Do not sell my data
Accessibility
Contact us
Affiliate program

Not logged in
- 49.34.168.28

Not affiliated

Springer Nature

© 2021 Springer Nature Switzerland AG. Part of Springer Nature.

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 31/32
11/30/21, 3:08 PM S-Adenosyl-L-Methionine | SpringerLink

https://link.springer.com/article/10.2165%2F00003495-198938030-00004 32/32